Metabolic & Cardiometabolic
statins decreases LDL cholesterol
In plain terms: Do statins lower LDL cholesterol?
Strong support Metabolic & Cardiometabolic 💰 Industry COI noted
Part of: 💊 statins
RefutedContestedStrong support
consensus score 1.00
Unambiguously yes — this is a direct, dose-dependent pharmacologic effect quantified across thousands of patients.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
5 support 0 contradict 0 tested null 0 mixed · 5 sources, 5 independent groups
The evidence (10)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Jones STELLAR 2003 · Am J Cardiol 2003 Jul 15;92(2):152-160 | RCT | supports | moderate | STELLAR, n=2,431 hypercholesterolemic adults (entry LDL 160-250 mg/dl) randomized to rosuvastatin, atorvastatin, simvastatin or pravastatin across dose ranges; 'a 6-week, parallel-group, open-label, randomized, multicenter trial' with NO placebo or untreated arm. LDL fell far enough on treatment that 'Adult Treatment Panel III LDL cholesterol goals were achieved by 82% to 89% of patients treated with rosuvastatin 10 to 40 mg compared with 69% to 85% of patients treated with atorvastatin 10 to 80 mg'. The efficacy contrasts are between statins, not against no statin: 'rosuvastatin 10 to 80 mg reduced LDL cholesterol by a mean of 8.2% more than atorvastatin 10 to 80 mg, 26% more than pravastatin 10 to 40 mg, and 12% to 18% more than simvastatin 10 to 80 mg'. Supports the claim via uncontrolled within-arm reduction to goal; quality moderate for open-label design, absent control arm, 6-week duration and surrogate endpoint. (Prior extract's absolute '26-63%' range is not in the readable text - the 26% is the between-drug difference versus pravastatin.) |
| Zhang 2020 · Cardiovasc Ther | meta-analysis | supports | high | Network meta-analysis of 50 RCTs (51956 participants) in dyslipidemia, cardiovascular disease or diabetes: all statins except lovastatin lowered LDL-C significantly versus placebo (rosuvastatin 72.28 mg/dL, 95% CI 57.08 to 87.48; atorvastatin 66.40, 55.10 to 77.71), and 'Rosuvastatin and atorvastatin ranked No. 1 and No. 2 in lowering LDL-C.' Doses were not standardised across trials — 'Second, the doses of statins used in the eligible studies were not unified' — so this is a class/agent comparison, not a dose-response analysis. |
| Cicero AFG, Cannon CP, Gautam R, Anwar S, Ghatak A, Sarnes E, Powell HA, Chhabra R, Jawla S 2026 · Atheroscler Plus | observational | tested-null | low | OFF-SCOPE for this claim: the exposure studied is bempedoic acid, not statins. Sponsor-funded SLR (Daiichi Sankyo; Esperion and Daiichi employees among the authors), 269 records screened, 28 reports on 22 real-world studies, MEDLINE/EMBASE/Cochrane to 19 Feb 2025. Explicitly NOT pooled: 'A meta-analysis was not conducted due to substantial heterogeneity ... Instead, a narrative synthesis was conducted.' Declared intervention: 'bempedoic acid monotherapy, bempedoic acid as a fixed-dose in combination with ezetimibe, or in combination with any other LLTs'; declared measurement: 'Most studies evaluated LDL-C changes from baseline after initiation of bempedoic acid.' Statins enter only as unchanged background therapy or as the population-defining intolerance status, so no analysis anywhere compares statin against no statin or isolates a statin's own LDL-C effect. Headline result is bempedoic acid's: 'LDL-C reductions of 15% to 39% when added to maximally tolerated statins, 22% to 38% in statin intolerant cohorts, and 18% to 42% in mixed statin intolerant cohorts.' The one statin-specific number in the paper is the comparator arm of a single included open-label trial (n=120): bempedoic acid 22.9% vs 'an 8% reduction with statin titration alone (p = 0.002)' - a dose-titration yield, a different claim, and second-hand. Corpus quality: 14 of 22 included studies are conference abstracts, only 8 full texts, of which NOS rated seven moderate and one low - none reached the low-risk band; no protocol registration; hsCRP, CV events and mortality were dropped from the synthesis for sparse reporting. |
| Sabatine, Wiviott, Im, Murphy, Giugliano 2018 · JAMA Cardiol. 2018 Sep 1;3(9):823-828 | meta-analysis | supports | high | OFF-SCOPE: this meta-analysis never measures how much statins lower LDL-C. LDL-C lowering is its exposure metric - the stated endpoint is 'the risk ratio (RR) of major vascular events ... per 1-mmol/L (38.7-mg/dL) reduction in LDL-C level' - and the statin limb gives only a control-arm level (mean 1.7 mmol/L), never a statin-versus-control delta. The single lowering magnitude reported is for the other drug class: 'Nonstatin therapy lowered LDL-C by 0.3 to 1.2 mmol/L (11 mg/dL to 45 mg/dL)'. Its statin data are also imported, not pooled ('The CTTC was used for statin data'). The previously stored ~22% was the paper's CTTC BACKGROUND figure at a 3.4 mmol/L baseline, not its own result (combined RR 0.79, 95% CI 0.71-0.87). |
| Liu 2026 · JACC Asia | RCT | supports | high | Multicentre double-placebo double-blind RCT (n=1,110, ENTRY / ChiCTR2200064214-5) with a directly randomized pharmaceutical statin arm: 'We enrolled 1,110 participants who were randomized into 4 groups to receive a 3-month intervention of placebo, NRYR (1,950 mg/d), simvastatin (20 mg/d), or NRYR (1,950 mg/d) plus simvastatin (20 mg/d).' Against placebo at the pre-specified 3-month primary endpoint, simvastatin 20 mg/d lowered LDL-C by '-25.80 mg/dL (95% CI: -32.64 to -18.97 mg/dL)/-17.08% (95% CI: -21.67% to -12.50%)'. Abstract-grade read (full text unavailable); the statin arm is not the sponsor-favourable arm, the trial being partly funded by supplement maker BYHEALTH. |
| Kritharides, Nicholls 2015 · Future Cardiol | meta-analysis | supports | high | COMMENTARY, no new data, and off-scope for this claim. The article is an 'Evaluation of: Fulcher et al. ... Lancet 385(9976), 1397-1405 (2015)'. It reports no LDL-C reduction magnitude anywhere: LDL lowering is the denominator of the effect estimate, not an outcome - 'statins reduced the risk of major vascular events by 21% for each mmol/l reduction of LDL cholesterol (relative risk: 0.79; 95% CI: 0.77-0.81)'. The only outcomes given are major vascular events and 'Total mortality was similarly and significantly reduced in men (10%) and women (9%).' The prior extract's phrase 'confirmed statins lower LDL-C' is not supported by the text. Zero-weighted per CONVENTIONS 5. |
| Gencer 2020 · Lancet | meta-analysis | supports | high | Off-scope for the LDL-lowering effect itself. The paper states 'We meta-analysed the risk ratio (RR) for major vascular events (a composite of cardiovascular death, myocardial infarction or other acute coronary syndrome, stroke, or coronary revascularisation) per 1 mmol/L reduction in LDL cholesterol' — LDL-C reduction is the denominator it normalises by, not an outcome it measures, and the abstract reports no achieved LDL-C value for any arm. The older cohort also mixes drug classes: '11 750 (54·7%) were from statin trials, 6209 (28·9%) from ezetimibe trials, and 3533 (16·4%) from PCSK9 inhibitor trials.' The prior extract asserted a confirmed LDL-C reduction this paper does not report. (Abstract-grade.) |
| Abbas 2026 · Future Cardiol | meta-analysis | supports | moderate | Off-scope for this claim. The pooled trials 'compared pitavastatin 2 mg or 4 mg plus ezetimibe 10 mg with pitavastatin 2 mg alone'; every arm was statin-treated, so no statin-free comparator exists and the abstract reports no monotherapy change-from-baseline. The prior extract's 'pitavastatin (with/without ezetimibe)' misread the design as a statin-presence contrast. |
| Heart Protection Study Collaborative Group 2002 · Lancet 2002 Jul 6;360(9326):7-22 | RCT | supports | high | HPS (n=20,536, 40 mg simvastatin vs placebo, 5 years): the randomised comparison 'yielded an average difference in LDL cholesterol of 1.0 mmol/L (about two-thirds of the effect of actual use of 40 mg simvastatin daily)' - i.e. ~1.0 mmol/L (~39 mg/dL) is the intention-to-treat difference, diluted by 85% compliance and 17% statin use in the placebo arm; actual use of the regimen lowers LDL by roughly half as much again. |
| Cholesterol Treatment Trialists 2005 · Lancet | meta-analysis | supports | high | Prospective IPD meta-analysis of 14 randomised statin trials (n=90,056): 'Mean LDL cholesterol differences at 1 year ranged from 0.35 mmol/L to 1.77 mmol/L (mean 1.09) in these trials' - the randomised statin-vs-control LDL reduction that all outcome effects were then standardised against. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.